BR112022022523A2 - ANTIBODIES AGAINST SARS-COV-2 - Google Patents
ANTIBODIES AGAINST SARS-COV-2Info
- Publication number
- BR112022022523A2 BR112022022523A2 BR112022022523A BR112022022523A BR112022022523A2 BR 112022022523 A2 BR112022022523 A2 BR 112022022523A2 BR 112022022523 A BR112022022523 A BR 112022022523A BR 112022022523 A BR112022022523 A BR 112022022523A BR 112022022523 A2 BR112022022523 A2 BR 112022022523A2
- Authority
- BR
- Brazil
- Prior art keywords
- cov
- antigen
- antibodies against
- sars
- sarscov
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 241001678559 COVID-19 virus Species 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
ANTICORPOS CONTRA SARSCOV-2. A presente descrição provê anticorpos e fragmentos de ligação a antígeno dos mesmos que podem se ligar a um antígeno SARS-CoV-2 e, em certas modalidades, são capazes de neutralizar potentemente uma infecção por SARS-CoV-2. Também são providos polinucleotídeos que codificam anticorpos e fragmentos de ligação a antígeno, vetores, células hospedeiras e composições e usos relacionados, inclusive para prevenir, tratar e diagnosticar uma infecção por SARSCoV-2 ou outro coronavírus.ANTIBODIES AGAINST SARSCOV-2. The present disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of potently neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides encoding antibodies and antigen-binding fragments, vectors, host cells, and related compositions and uses, including for preventing, treating, and diagnosing an infection by SARSCoV-2 or another coronavirus.
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063022392P | 2020-05-08 | 2020-05-08 | |
US202063024372P | 2020-05-13 | 2020-05-13 | |
US202063027814P | 2020-05-20 | 2020-05-20 | |
US202063029338P | 2020-05-22 | 2020-05-22 | |
US202063031286P | 2020-05-28 | 2020-05-28 | |
US202063033045P | 2020-06-01 | 2020-06-01 | |
US202063036683P | 2020-06-09 | 2020-06-09 | |
US202063039939P | 2020-06-16 | 2020-06-16 | |
US202063046465P | 2020-06-30 | 2020-06-30 | |
US202063057767P | 2020-07-28 | 2020-07-28 | |
US202063090667P | 2020-10-12 | 2020-10-12 | |
US202063113450P | 2020-11-13 | 2020-11-13 | |
US202163153784P | 2021-02-25 | 2021-02-25 | |
US202163170368P | 2021-04-02 | 2021-04-02 | |
PCT/US2021/031442 WO2021226560A1 (en) | 2020-05-08 | 2021-05-07 | Antibodies against sars-cov-2 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022022523A2 true BR112022022523A2 (en) | 2023-01-10 |
Family
ID=76250434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022022523A BR112022022523A2 (en) | 2020-05-08 | 2021-05-07 | ANTIBODIES AGAINST SARS-COV-2 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4146690A1 (en) |
JP (1) | JP2023525039A (en) |
KR (1) | KR20230010676A (en) |
AU (1) | AU2021268361A1 (en) |
BR (1) | BR112022022523A2 (en) |
CA (1) | CA3177169A1 (en) |
CL (1) | CL2022003085A1 (en) |
CO (1) | CO2022017670A2 (en) |
IL (1) | IL297988A (en) |
MX (1) | MX2022013886A (en) |
WO (1) | WO2021226560A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202146442A (en) | 2020-02-26 | 2021-12-16 | 美商維爾生物科技股份有限公司 | Antibodies against sars-cov-2 and methods of using the same |
JP7116256B1 (en) | 2020-04-02 | 2022-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Anti-SARS-COV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments |
BR112022024662A2 (en) | 2020-06-03 | 2023-04-04 | Regeneron Pharma | METHODS FOR TREATMENT OR PREVENTION OF SARS-COV-2 AND COVID-19 INFECTIONS WITH ANTI-SARS-COV-2 SPIKE GLYCOPROTEIN ANTIBODIES |
CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
KR20230058434A (en) | 2020-08-26 | 2023-05-03 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | Antigen binding molecules targeting SARS-CoV-2 |
WO2022263638A1 (en) * | 2021-06-17 | 2022-12-22 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
BR112024000744A2 (en) * | 2021-07-14 | 2024-04-30 | Regeneron Pharma | ANTI-SARS-COV-2 SPIKE GLYCOPROTEIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS |
WO2023201256A1 (en) * | 2022-04-12 | 2023-10-19 | Vir Biotechnology, Inc. | High dose antibody therapies for sars-cov-2 infection |
US11993644B2 (en) | 2022-05-06 | 2024-05-28 | Generate Biomedicines, Inc. | Antigen binding molecules targeting SARS-CoV-2 |
WO2023224714A1 (en) * | 2022-05-16 | 2023-11-23 | Lawrence Livermore National Security, Llc | Repaired therapeutic and prophylactic antibodies against sars-cov-2 variants |
WO2023235827A2 (en) * | 2022-06-03 | 2023-12-07 | The Rockefeller University | Coronavirus-inhibiting antibodies |
WO2024006472A1 (en) | 2022-06-30 | 2024-01-04 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
WO2024081269A1 (en) * | 2022-10-10 | 2024-04-18 | Dixit Rohan | Therapeutic combinations and methods to treat long covid |
WO2024102674A1 (en) | 2022-11-13 | 2024-05-16 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
CN117362421A (en) * | 2022-12-02 | 2024-01-09 | 中国科学院微生物研究所 | Broad-spectrum monoclonal antibody for novel coronavirus RBD, preparation method and application thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
CA2385347C (en) | 1999-10-04 | 2009-12-15 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
EP1597280B2 (en) | 2003-02-26 | 2016-08-24 | Institute for Research in Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
EP1676862B1 (en) | 2003-09-24 | 2010-12-22 | Kyowa Hakko Kirin Co., Ltd. | Recombinant antibody against human insulin-like growth factor |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
CA2931641C (en) | 2013-12-30 | 2022-05-10 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
WO2016181357A1 (en) | 2015-05-13 | 2016-11-17 | Zumutor Biologics, Inc. | Afucosylated protein, cell expressing said protein and associated methods |
WO2019024979A1 (en) | 2017-07-31 | 2019-02-07 | Institute For Research In Biomedicine | Antibodies with functional domains in the elbow region |
WO2019057122A1 (en) | 2017-09-22 | 2019-03-28 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific polypeptide complexes |
-
2021
- 2021-05-07 CA CA3177169A patent/CA3177169A1/en active Pending
- 2021-05-07 EP EP21729694.6A patent/EP4146690A1/en active Pending
- 2021-05-07 WO PCT/US2021/031442 patent/WO2021226560A1/en active Application Filing
- 2021-05-07 KR KR1020227043022A patent/KR20230010676A/en unknown
- 2021-05-07 IL IL297988A patent/IL297988A/en unknown
- 2021-05-07 AU AU2021268361A patent/AU2021268361A1/en active Pending
- 2021-05-07 BR BR112022022523A patent/BR112022022523A2/en not_active Application Discontinuation
- 2021-05-07 JP JP2022567512A patent/JP2023525039A/en active Pending
- 2021-05-07 MX MX2022013886A patent/MX2022013886A/en unknown
-
2022
- 2022-11-07 CL CL2022003085A patent/CL2022003085A1/en unknown
- 2022-12-06 CO CONC2022/0017670A patent/CO2022017670A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL297988A (en) | 2023-01-01 |
KR20230010676A (en) | 2023-01-19 |
AU2021268361A1 (en) | 2022-12-08 |
EP4146690A1 (en) | 2023-03-15 |
CO2022017670A2 (en) | 2023-03-07 |
CL2022003085A1 (en) | 2023-09-01 |
JP2023525039A (en) | 2023-06-14 |
CA3177169A1 (en) | 2021-11-11 |
WO2021226560A1 (en) | 2021-11-11 |
MX2022013886A (en) | 2022-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022022523A2 (en) | ANTIBODIES AGAINST SARS-COV-2 | |
BR112022017048A2 (en) | ANTIBODIES AGAINST SARS-COV-2 AND METHODS FOR USING THEM | |
BR112022015374A2 (en) | ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USE THEREOF | |
BR112022020706A2 (en) | ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF THEIR USE | |
BR112015026258A2 (en) | therapeutic and immunomodulatory compositions and agents, and uses thereof | |
BR112018074463A2 (en) | anti-tim-3 antibodies and methods of use. | |
BR112012018951A8 (en) | monoclonal antibody, pharmaceutical composition, pharmaceutical combination, use of an antibody, use of a pharmaceutical composition and use of a pharmaceutical combination | |
BR112016025009A2 (en) | Human Antibodies to Middle East Respiratory Syndrome - Surface Protein | |
BR112014021251A2 (en) | human antibodies to clostridium difficile toxins | |
BR112020015915A8 (en) | USES OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA4 ANTIBODY OR ANTIGEN-BINDING FRAGMENTS THEREOF, AS WELL AS A KIT FOR TREATMENT OF A PATIENT WITH CANCER | |
BR112016013347A2 (en) | anti-il-33 neutralizing human monoclonal antibody | |
BR112012018947B1 (en) | monoclonal anti-caprin-1 antibody, pharmaceutical composition, pharmaceutical combination and uses of a pharmaceutical composition, an antibody and a pharmaceutical combination | |
BR112012022214A2 (en) | methods and compositions for treating degum disease | |
BR112014012607A2 (en) | treatment methods using an interferon gamma inhibitor | |
BRPI0906478B8 (en) | anti-nr10 antibody, its use and pharmaceutical composition comprising it | |
BR112022013236A2 (en) | ANTI-CD73 ANTIBODIES AND USES THEREOF | |
BR112015030892A2 (en) | ANTIGEN-BINDING PROTEIN, MONOCLONAL ANTIBODY, RECOMBINANT NUCLEIC ACID, EXPRESSION VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION, USE OF AN ANTIGEN-BINDING PROTEIN OR HUMANIZED ANTIBODY, AND METHOD FOR PRODUCING AN ANTIGEN-BINDING PROTEIN | |
BR112023005684A2 (en) | ANTIBODIES AGAINST SARS-COV-2 | |
BR112022023088A2 (en) | ANTIBODIES AGAINST SARS-COV-2 AND SELECTION METHODS AND THEIR USE | |
BR112022001341A2 (en) | enzyme inhibitors | |
AR066396A1 (en) | ANTI-R7V ANTIBODIES AND USES OF THE SAME | |
BR112021016272A2 (en) | Humanized anti-dll3 chimeric antigen receptors and uses thereof | |
BR112021016398A2 (en) | CD33 antibodies and methods of using them to treat cancer | |
BR112022022503A2 (en) | NEUTRALIZING ANTIBODIES THAT BIND TO SARS-COV-2 S PROTEIN | |
BR112013032456A2 (en) | anti-cxcr4 antibody with effector functions and its use for cancer treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing |